Peter J. Webb
Amplyx Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Diabetes Treatment and Management, Antifungal resistance and susceptibility, Neuropeptides and Animal Physiology, Immune Cell Function and Interaction
Most-Cited Works
- → In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus(2018)115 cited
- → 3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice(2008)93 cited
- → Studies on the immunobiology of rnu/rnu “nude” rats with congenital aplasia of the thymus(1980)84 cited
- → 1-Alkyl-benzotriazole-5-carboxylic Acids Are Highly Selective Agonists of the Human Orphan G-Protein-Coupled Receptor GPR109b(2006)80 cited
- → (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans(2012)51 cited
- → Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a(2007)36 cited
- → Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a)(2010)32 cited
- → Agonist lead identification for the high affinity niacin receptor GPR109a(2007)29 cited
- → 3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b(2007)27 cited
- → A calcineurin antifungal strategy with analogs of FK506(2017)26 cited